ArticleThe Lancet regional health. Europe2022
Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany.
Article in The Lancet regional health. Europe, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.Future oncology (London, England) · 2025Pooled it
- Polymerase Chain Reaction on Respiratory Tract Specimens of Immunocompromised Patients to Diagnose Pneumocystis Pneumonia: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Pooled it
- Outcomes of concomitantAnnals of medicine · 2026Article
- Prophylaxis Regimens forJournal of fungi (Basel, Switzerland) · 2026Review
- The role of cancer and immunosuppression in pneumocystis pneumonia: a large comprehensive population-based study.Infection · 2026Article
- Decreasing admissions in older and increasing mortality in younger patients: a nationwide observational study of all German ICU cases 2011-2022.Critical care (London, England) · 2026Observational
- Combined Serum (1,3)-β-D-Glucan and Oral Wash PCR as a Noninvasive Diagnostic Strategy for Early Detection ofOpen forum infectious diseases · 2026Article
- Construction of a Diagnostic Model for Pneumocystis Jirovecii Pneumonia in HIV-Negative Patients Based on Single-Center Patient Data.Infection and drug resistance · 2026Article
- Challenges and solutions in determining urolithiasis caseloads using the digital infrastructure of a clinical data warehouse.PloS one · 2026Article
- Research progress on the current status of respiratory pathogen infections and their detection methods.Frontiers in microbiology · 2026Review
- Fungal Infection in HIV-Infected Patients-Is It Still a Challenge?Journal of clinical medicine · 2025Review
- Mortality ofAnnals of medicine · 2025Article
- Article
- Article
- Estimated burden of serious mycoses in Poland.Scientific reports · 2025Article
- The 2025 EQUALJAC-antimicrobial resistance · 2025Article
- Review
- Clinician opinions on starting treatment for opportunistic infection prevention in interstitial lung disease: the STOP-ILD study.ERJ open research · 2025Article
- Clinical Factors Associated With Pneumocystis Pneumonia Despite Its Primary Prophylaxis: When to Stop Prophylaxis?Arthritis & rheumatology (Hoboken, N.J.) · 2025Observational
- Differentiation of Pneumocystis jirovecii pneumonia from colonization: a clinical decision framework incorporating risk stratification and next-generation sequencing thresholds.BMC infectious diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pneumocystis pneumonia (PCP) is a life-threatening opportunistic infectious disease of immunocompromised patients. Its incidence has decreased worldwide in the past, but data concerning its recent epidemiology are lacking. Methods: We retrospectively analyzed all German inpatient cases from January 1, 2014 to December 31, 2019, to describe the recent epidemiology, incidence, clinical course, mortality and underlying diseases of PCP. Simultaneously, we conducted a retrospective multi-center study at two German university hospitals, and analyzed PCP cases treated there to gain deeper insights on the basis of primary patient data. Findings: The incidence of PCP significantly increased from 2·3 to 2·6 per 100,000 population from 2014 to 2019 (1,857 to 2,172 cases, +17·0%, Interpretation: The incidence of PCP has reversed its trend, showing a significant increase in mortality on population level. Patients who were not previously considered in prophylactic measures are increasingly affected by PCP. This development deserves further investigation, and additional comprehensive guidelines for the use of chemoprophylaxis in new risk groups are needed. Funding: Department of Nephrology and Hypertension, University Hospital Schleswig-Holstein, Kiel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.